Editorial commentary: Pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 178-179

  Egelund, Eric F ^a   Peloquin, Charles A ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; EFAVIRENZ; ISONIAZID; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84864131480     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis366     Document Type: Note

References (12)

1. Pasipanodya J, Srivastava S, Gumbo T. Metaanalysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
2. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481-91. (Pubitemid 40628637)
3. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49:1305-11.
4. Taylor S, Jayasuriya A, Fisher M, et al. Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. J Antimicrob Chemother 2012; 67:675-80.
5. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-7. (Pubitemid 43122320)
6. Zhang M, Li SY, Rosenthal IM, et al. Treatment of tuberculosis with rifamycincontaining regimens in immune-deficient mice. Am J Respir Crit Care Med 2011; 183: 1254-61.
7. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:1153-8. (Pubitemid 44772087)
8. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327:1817-8.
9. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83. (Pubitemid 35252827)
10. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16:1546-53.
11. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48:2951-7. (Pubitemid 38989160)
12. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 2008; 88(Suppl 1):S65-74.